H. Lee Moffitt Cancer Center and Research Institute
moffitt.orgTotal trials
534
Active
147
Phase 3
5
Total enrollment
68,586
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 164 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| F-DCFPyL | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | 28 | |||
| Pembrolizumab | — | — | — | — | 17 | ||
| Cyclophosphamide | — | — | — | 23 | |||
| Ipilimumab | — | — | 15 | ||||
| Fludarabine | — | — | 14 | ||||
| Trastuzumab | — | — | — | — | 7 | ||
| Docetaxel | — | — | — | 10 | |||
| Interleukin-2 | — | — | — | 9 | |||
| Ruxolitinib | — | — | — | — | 5 | ||
| Sacituzumab govitecan | — | — | — | — | — | 3 | |
| Vincristine | — | — | — | 6 | |||
| Paclitaxel | — | — | — | — | 11 | ||
| Prednisone | — | — | — | — | 5 | ||
| Pertuzumab | — | — | — | — | — | 4 | |
| Azacitidine | — | — | — | — | 4 | ||
| Rituximab | — | — | — | — | 4 | ||
| Cemiplimab | — | — | — | — | 3 | ||
| Abiraterone | — | — | — | — | 2 | ||
| Binimetinib | — | — | — | — | 2 | ||
| Abemaciclib | — | — | — | — | — | 2 | |
| Decitabine | — | — | — | — | 2 | ||
| Venetoclax | — | — | — | — | — | 2 | |
| Gemcitabine | — | — | — | 16 | |||
| Dexamethasone | — | — | — | 12 | |||
| Carboplatin | — | — | — | 12 | |||
| Vinorelbine | — | — | — | — | 3 | ||
| Lenalidomide | — | — | — | — | 12 | ||
| Cisplatin | — | — | — | — | 7 | ||
| Pemetrexed | — | — | — | — | 5 | ||
| Vorinostat | — | — | — | — | 3 | ||
| Cetuximab | — | — | — | — | — | 3 | |
| Enzalutamide | — | — | — | — | 3 | ||
| Axitinib | — | — | — | — | — | 3 | |
| Oxaliplatin | — | — | — | — | — | 3 | |
| Bortezomib | — | — | — | — | — | 3 | |
| Atezolizumab | — | — | — | — | 2 | ||
| HER-2 pulsed DC1 | — | — | — | — | — | 2 | |
| Nivolumab + Relatlimab | — | — | — | — | 2 | ||
| Ribociclib | — | — | — | — | 2 |
124 more active programs hidden
Next readouts
- 2019-08-12
- 2019-10-31
- 2022-04-06
- 2022-06-22
- 2022-09-19
- 2023-06-01
- 2023-10-09
- 2023-11-08
- 2023-11-28
- 2024-01-21
Top conditions
- Breast Cancer39
- Prostate Cancer26
- Multiple Myeloma23
- Pancreatic Cancer23
- Lung Cancer22
- Smoking Cessation17
- Melanoma16
- Leukemia15
Frequently asked questions about H. Lee Moffitt Cancer Center and Research Institute
- How many clinical trials does H. Lee Moffitt Cancer Center and Research Institute have on ClinicalTrials.gov?
- H. Lee Moffitt Cancer Center and Research Institute is listed as the lead sponsor on 534 clinical trials in ClinicalTrials.gov, 147 of which are currently active (recruiting, enrolling, or ongoing).
- How many of H. Lee Moffitt Cancer Center and Research Institute's trials are in Phase 3?
- 5 of H. Lee Moffitt Cancer Center and Research Institute's trials are in Phase 3, spread across 164 active drug programs.
- What therapeutic areas does H. Lee Moffitt Cancer Center and Research Institute focus on?
- H. Lee Moffitt Cancer Center and Research Institute's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Multiple Myeloma, Pancreatic Cancer, Lung Cancer.
- When are H. Lee Moffitt Cancer Center and Research Institute's next clinical trial readouts?
- H. Lee Moffitt Cancer Center and Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer”, expected around 2019-08-12.